MedKoo Cat#: 205742 | Name: NKP-2235

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NKP-2235, also known as IT-235, is a first-in-class orally available gallium-based anticaner small molecule that targets the endoplasmic reticulum with a unique pattern of cytotoxicity. NKP-2235 IND has been cleared and a Phase I trial will be initiated shortly. NKP-2235 were discovered by Professor Bernhard Keppler, University of Vienna, Austria.

Chemical Structure

NKP-2235
CAS#NONE

Theoretical Analysis

MedKoo Cat#: 205742

Name: NKP-2235

CAS#: NONE

Chemical Formula:

Exact Mass:

Molecular Weight:

Elemental Analysis:

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
NKP2235; NKP 2235; NKP-2235; IT-235; IT235; IT 235.
IUPAC/Chemical Name
NONE
InChi Key
InChi Code
SMILES Code
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
NKP-2235 is a first-in-class targeted gallium-based small molecule. It is orally bioavailable and given as a tablet. NKP-2235, is currently being developed by Niiki Pharma. According to its website,  NKP-2235 targets the endoplasmic reticulum. Unlike normal cells, tumor cells are known to be under high levels of stress due to factors such as hypoxia, acidosis and glucose deprivation. This leads to high levels of protein misfolding and other stress effects. Endoplasmic reticulum is the cell machinery that repairs protein misfolding. In tumor cells, the endoplasmic reticulum in is under stress due to the high levels of misfolded proteins and other factors. NKP-2235 induces additional endoplasmic reticulum stress, leading to an overload of the system, which triggers tumor cell death.    

Preparing Stock Solutions

The following data is based on the product molecular weight 0.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL